GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

The drugmaker says an oral version of Wegovy improved Alzheimer’s-related biomarkers, but didn’t delay the disease’s ...

Johnson & Johnson ends its Phase 2b posdinemab trial after missing key Alzheimer's goals, raising concerns for ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

A promising Alzheimer’s treatment failed to slow the progress of the disease, news that could dampen enthusiasm for a new class of potential medicines.

Two large-scale phase 3 trials found that semaglutide did not significantly slow cognitive decline in early-stage Alzheimer’s ...

Novo Nordisk NVO announced Monday that its oral GLP-1 called Rybelsus wasn’t better than a placebo at delaying the progression of Alzheimer’s disease. It shared few details beyond saying the ...

The results from the two trials of early-stage Alzheimer's patients, called EVOKE and EVOKE+, are another setback for the ...

A new study shows that lecanemab, an amyloid-clearing Alzheimer’s therapy, does not improve the brain’s waste-removal network ...

The lab, led by Carleara Weiss, explores the relationship between Alzheimer’s disease and biomarkers of neurodegeneration, ...